Immunotherapeutic interventions in chronic hepatitis B virus infection: A review

Journal of Immunological Methods

Volumn 407, Issue , 2014, Pages 1-8

  Wang, Li ^a   Zou, Zhi Qiang ^a   Liu, Cheng Xia ^b   Liu, Xiang Zhong ^a  

^a Infectious Disease Hospital of Yantai   (China)

^b BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Antiviral agents; Chronic hepatitis B; Immune based therapy; Immunity; Immunotherapeutic intervention

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; ENTECAVIR; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 12; LAMIVUDINE; PEGINTERFERON ALPHA; TELBIVUDINE; TENOFOVIR; THYMOSIN; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DECOMPENSATED LIVER CIRRHOSIS; HELPER CELL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LIVER CELL CARCINOMA; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TREATMENT DURATION; VIRUS REPLICATION;

HEPATITIS B VIRUS;

ANTIVIRAL AGENTS; CHRONIC HEPATITIS B; IMMUNE-BASED THERAPY; IMMUNITY; IMMUNOTHERAPEUTIC INTERVENTION;

ANIMALS; ANTIVIRAL AGENTS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; VIRUS REPLICATION;

EID: 84901398058     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2014.04.004     Document Type: Review

References (93)

1. Aalaei-Andabili S.H., Alavian S.M. Regulatory T cells are the most important determinant factor of hepatitis B infection prognosis: a systematic review and meta-analysis. Vaccine 2012, 30(38):5595.
2. Ait-Goughoulte M., Lucifora J., Zoulim F., Durantel D. Innate antiviral immune responses to hepatitis B virus. Viruses 2010, 2(7):1394.
3. Akbar S.M., Yoshida O., Chen S., Cesar A.J., Abe M., Matsuura B., Hiasa Y., Onji M. Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection. Antivir. Ther. 2010, 15(6):887.
4. Akbar S.M., Chen S., Al-Mahtab M., Abe M., Hiasa Y., Onji M. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus. Antivir. Res. 2012, 96(1):59.
5. Apostolopoulos V., Thalhammer T., Tzakos A.G., Stojanovska L. Targeting antigens to dendritic cell receptors for vaccine development. J. Drug Deliv. 2013, 2013:869718. (Epub 2013 Oct 8).
6. Barton G.M. Viral recognition by Toll-like receptors. Semin. Immunol. 2007, 19(1):33.
7. Bertoletti A., Tan A.T., Gehring A.J. HBV-specific adaptive immunity. Viruses 2009, 1(2):91.
8. Boni C., Penna A., Bertoletti A., Lamonaca V., Rapti I., Missale G., Pilli M., Urbani S., Cavalli A., Cerioni S., Panebianco R., Jenkins J., Ferrari C. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J. Hepatol. 2003, 39(4):595.
9. Boni C., Fisicaro P., Valdatta C., Amadei B., Di Vincenzo P., Giuberti T., Laccabue D., Zerbini A., Cavalli A., Missale G., Bertoletti A., Ferrari C. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 2007, 81(8):4215.
10. Boni C., Laccabue D., Lampertico P., Giuberti T., Viganò M., Schivazappa S., Alfieri A., Pesci M., Gaeta G.B., Brancaccio G., Colombo M., Missale G., Ferrari C. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012, 143(4). (963-73.e9).
11. Bourgine M., Dion S., Godon O., Guillen G., Michel M.L., Aguilar J.C. Optimization of immune responses induced by therapeutic vaccination with cross-reactive antigens in a humanized hepatitis B surface antigen transgenic mouse model. Virology 2012, 430(1):10.
12. Buchmann P., Dembek C., Kuklick L., Jäger C., Tedjokusumo R., von Freyend M.J., Drebber U., Janowicz Z., Melber K., Protzer U. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 2013, 31(8):1197.
13. Chen W., Zhang Z., Shi M., Chen L., Fu J., Shi F., Zhang B., Zhang H., Jin L., Wang F.S. Activated plasmacytoid dendritic cells act synergistically with hepatitis B core antigen-pulsed monocyte-derived dendritic cells in the induction of hepatitis B virus-specific CD8 T-cell response. Clin. Immunol. 2008, 129(2):295. (Nov).
14. Chen J.H., Yu Y.S., Liu H.H., Chen X.H., Xi M., Zang G.Q., Tang Z.H. Ubiquitin conjugation of hepatitis B virus core antigen DNA vaccine leads to enhanced cell-mediated immune response in BALB/c mice. Hepat. Mon. 2011, 11(8):620.
15. Chou Y.C., Chen M.L., Hu C.P., Chen Y.L., Chong C.L., Tsai Y.L., Liu T.L., Jeng K.S., Chang C. Transforming growth factor-beta1 suppresses hepatitis B virus replication primarily through transcriptional inhibition of pregenomic RNA. Hepatology 2007, 46(3):672.
16. Crettaz J., Otano I., Ochoa-Callejero L., Benito A., Paneda A., Aurrekoetxea I., Berraondo P., Rodríguez-Madoz J.R., Astudillo A., Kreppel F., Kochanek S., Ruiz J., Menne S., Prieto J., Gonzalez-Aseguinolaza G. Treatment of chronic viral hepatitis in woodchucks by prolonged intrahepatic expression of interleukin-12. J. Virol. 2009, 83(6):2663.
17. Das A., Ellis G., Pallant C., Lopes A.R., Khanna P., Peppa D., Chen A., Blair P., Dusheiko G., Gill U., Kennedy P.T., Brunetto M., Lampertico P., Mauri C., Maini M.K. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J. Immunol. 2012, 189(8):3925.
18. Enomoto M., Tamori A., Nishiguchi S., Kawada N. Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. J. Gastroenterol. 2013, 48(9):999-1005.
19. European Association For The Study Of The Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 2012, 57(1):167.
20. Farag M.M., Tedjokusumo R., Flechtenmacher C., Asen T., Stremmel W., Müller M., Protzer U., Weigand K. Immune tolerance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp. Vaccine 2012, 30(42):6034.
21. Fisicaro P., Valdatta C., Massari M., Loggi E., Biasini E., Sacchelli L., Cavallo M.C., Silini E.M., Andreone P., Missale G., Ferrari C. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010, 138(2):682.
22. Fletcher S.P., Delaney W.E. New therapeutic targets and drugs for the treatment of chronic hepatitis B. Semin. Liver Dis. 2013, 33(2):130.
23. Gehring A.J., Xue S.A., Ho Z.Z., Teoh D., Ruedl C., Chia A., Koh S., Lim S.G., Maini M.K., Stauss H., Bertoletti A. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J. Hepatol. 2011, 55(1):103.
24. Grimm D., Thimme R., Blum H.E. HBV life cycle and novel drug targets. Hepatol. Int. 2011, 5(2):644.
25. Guiducci C., Coffman R.L., Barrat F.J. Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J. Intern. Med. 2009, 265(1):43.
26. He D., Yan G., Wang Y. Serum levels of interleukin-12 in various clinical states with hepatitis B virus infection. Cell. Immunol. 2012, 272(2):162.
27. Hong M.H., Chou Y.C., Wu Y.C., Tsai K.N., Hu C.P., Jeng K.S., Chen M.L., Chang C. Transforming growth factor-β1 suppresses hepatitis B virus replication by the reduction of hepatocyte nuclear factor-4α expression. PLoS One 2012, 7(1):e30360.
28. Huang R., Hao Y., Zhang J., Wu C. Interferon-alpha plus adefovir combination therapy versus interferon-alpha monotherapy for chronic hepatitis B treatment: a meta-analysis. Hepatol. Res. 2013, 43(10):1040-1051.
29. Im S.J., Yang S.H., Yoon S.K., Sung Y.C. Increase of plasma IL-12/p40 ratio induced by the combined therapy of DNA vaccine and lamivudine correlates with sustained viremia control in CHB carriers. Immune Netw. 2009, 9(1):20.
30. Jiang Y.F., Ma Z.H., Zhao P.W., Pan Y., Liu Y.Y., Feng J.Y., Niu J.Q. Effect of thymosin-α(1) on T-helper 1 cell and T-helper 2 cell cytokine synthesis in patients with hepatitis B virus e antigen-positive chronic hepatitis B. J. Int. Med. Res. 2010, 38(6):2053.
31. Ju Y., Hou N., Meng J., Wang X., Zhang X., Zhao D., Liu Y., Zhu F., Zhang L., Sun W., Liang X., Gao L., Ma C. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J. Hepatol. 2010, 52(3):322.
32. Kim B.H., Lee Y.J., Kim W., Yoon J.H., Jung E.U., Park S.J., Kim Y.J., Lee H.S. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study. Scand. J. Gastroenterol. 2012, 8-9(47):1048.
33. Koay L.B., Feng I.C., Sheu M.J., Kuo H.T., Lin C.Y., Chen J.J., Wang S.L., Tang L.Y., Tsai S.L. Hepatitis B virus (HBV) core antigen-specific regulatory T cells confer sustained remission to anti-HBV therapy in chronic hepatitis B with acute exacerbation. Hum. Immunol. 2011, 72(9):687.
34. Kondo Y., Ueno Y., Kobayashi K., Kakazu E., Shiina M., Inoue J., Tamai K., Wakui Y., Tanaka Y., Ninomiya M., Obara N., Fukushima K., Ishii M., Kobayashi T., Niitsuma H., Kon S., Shimosegawa T. Hepatitis B virus replication could enhance regulatory T cell activity by producing soluble heat shock protein 60 from hepatocytes. J. Infect. Dis. 2010, 202(2):202.
35. Kondo Y., Ueno Y., Shimosegawa T. Toll-like receptors signaling contributes to immunopathogenesis of HBV infection. Gastroenterol. Res. Pract. 2011, 2011:810939.
36. Lang T., Lo C., Skinner N., Locarnini S., Visvanathan K., Mansell A. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J. Hepatol. 2011, 55(4):762.
37. Lau G., Marcellin P., Peters M. Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies. Hepatol. Int. 2007, 1(2):316.
38. Lee H.W., Lee J.I., Um S.H., Ahn S.H., Chang H.Y., Park Y.K., Hong S.P., Moon Y.M., Han K.H. Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: a prospective randomized, comparative pilot study. J. Gastroenterol. Hepatol. 2008, 23(5):729.
39. Liang M., Ma S., Hu X., Zhou B., Zhang J., Chen J., Wang Z., Sun J., Zhu X., Abbott W., Hou J. Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy. Virol. J. 2011, 14(8):69.
40. Liaw Y.F. Impact of therapy on the outcome of chronic hepatitis B. Liver Int. 2013, 33(Suppl. 1):111.
41. Lin C., Zhu J., Zheng Y., Chen Y., Wu Z., Chong Y., Gao Z. Effect of GM-CSF in combination with hepatitis B vaccine on revaccination of healthy adult non-responders. J. Infect. 2010, 60(4):264.
42. Liu Y.Z., Hou F.Q., Ding P., Ren Y.Y., Li S.H., Wang G.Q. Pegylated interferon α enhances recovery of memory T cells in e antigen positive chronic hepatitis B patients. Virol. J. 2012, 9:274.
43. Loggi E., Bihl F.K., Cursaro C., Granieri C., Galli S., Brodosi L., Furlini G., Bernardi M., Brander C., Andreone P. Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels. PLoS One 2013, 8(6):e65327.
44. Löhr H.F., Pingel S., Böcher W.O., Bernhard H., Herzog-Hauff S., Rose-John S., Galle P.R. Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B-restoration by exogenous interleukin-12. Clin. Exp. Immunol. 2002, 130(1):107.
45. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661.
46. Lu G.F., Tang F.A., Zheng P.Y., Yang P.C., Qi Y.M. Entecavir up-regulates dendritic cell function in patients with chronic hepatitis B. World J. Gastroenterol. 2008, 14(10):1617.
47. Lu M., Yao X., Xu Y., Lorenz H., Dahmen U., Chi H., Dirsch O., Kemper T., He L., Glebe D., Gerlich W.H., Wen Y., Roggendorf M. Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model. J. Virol. 2008, 82(5):2598.
48. Maini M.K., Peppa D. NK cells: a double-edged sword in chronic hepatitis B virus infection. Front. Immunol. 2013, 4:57. (Epub 2013 Mar 1).
49. Martinet J., Leroy V., Dufeu-Duchesne T., Larrat S., Richard M.J., Zoulim F., Plumas J., Aspord C. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection. Hepatology 2012, 56(5):1706.
50. Morrey J.D., Motter N.E., Chang S., Fairman J. Breaking B and T cell tolerance using cationic lipid-DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV. Antivir. Res. 2011, 90(3):227.
51. Nebbia G., Peppa D., Maini M.K. Hepatitis B infection: current concepts and future challenges. QJM 2012, 105(2):109.
52. Nebbia G., Peppa D., Schurich A., Khanna P., Singh H.D., Cheng Y., Rosenberg W., Dusheiko G., Gilson R., ChinAleong J., Kennedy P., Maini M.K. Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One 2012, 7(10):e47648.
53. Obeng-Adjei N., Choo D.K., Saini J., Yan J., Pankhong P., Parikh A., Chu J.S., Weiner D.B. Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver. Cancer Gene Ther. 2012, 19(11):779.
54. Op den Brouw M.L., Binda R.S., van Roosmalen M.H., Protzer U., Janssen H.L., van der Molen R.G., Woltman A.M. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 2009, 126(2):280.
55. Overton E.T., Sungkanuparph S., Klebert M., Royal M., Demarco-Shaw D., Powderly W.G., Aberg J.A. GM-CSF fails to improve immune responses to booster hepatitis B vaccination in HIV-infected individuals. Open Virol. J. 2011, 5:109.
56. Pagliaccetti N.E., Robek M.D. Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus. J. Interferon Cytokine Res. 2010, 30(8):585.
57. Peppa D., Micco L., Javaid A., Kennedy P.T., Schurich A., Dunn C., Pallant C., Ellis G., Khanna P., Dusheiko G., Gilson R.J., Maini M.K. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog. 2010, 6(12):e1001227.
58. Peppa D., Gill U.S., Reynolds G., Easom N.J., Pallett L.J., Schurich A., Micco L., Nebbia G., Singh H.D., Adams D.H., Kennedy P.T., Maini M.K. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J. Exp. Med. 2013, 210(1):99.
59. Phillips S., Chokshi S., Riva A., Evans A., Williams R., Naoumov N.V. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J. Immunol. 2010, 184(1):287.
60. Qing Y., Chen M., Zhao J., Hu H., Xu H., Ling N., Peng M., Ren H. Construction of an HBV DNA vaccine by fusion of the GM-CSF gene to the HBV-S gene and examination of its immune effects in normal and HBV-transgenic mice. Vaccine 2010, 28(26):4301.
61. Raziorrouh B., Schraut W., Gerlach T., Nowack D., Grüner N.H., Ulsenheimer A., Zachoval R., Wächtler M., Spannagl M., Haas J., Diepolder H.M., Jung M.C. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology 2010, 52(6):1934.
62. Reijnders J.G., Perquin M.J., Zhang N., Hansen B.E., Janssen H.L. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010, 139(2):491.
63. Ren G.L., Huang G.Y., Zheng H., Fang Y., Ma H.H., Xu M.C., Zhang H.B., Zhang W.Y., Zhao Y.G., Sun D.Y., Hu W.K., Liu J. Changes in innate and permissive immune responses after HBV transgenic mouse vaccination and long-term-siRNA treatment. PLoS One 2013, 8(3):e57525.
64. Rigopoulou E.I., Suri D., Chokshi S., Mullerova I., Rice S., Tedder R.S., Williams R., Naoumov N.V. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology 2005, 42(5):1028.
65. Schurich A., Khanna P., Lopes A.R., Han K.J., Peppa D., Micco L., Nebbia G., Kennedy P.T., Geretti A.M., Dusheiko G., Maini M.K. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 2011, 53(5):1494.
66. Schurich A., Pallett L.J., Lubowiecki M., Singh H.D., Gill U.S., Kennedy P.T., Nastouli E., Tanwar S., Rosenberg W., Maini M.K. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog. 2013, 9(3):e1003208. (Epub 2013 Mar 14).
67. Schwarz K., Storni T., Manolova V., et al. Role of toll-like receptors in costimulating cytotoxic T cell responses. Eur. J. Immunol. 2003, 33(6):1465.
68. Senturk H., Tabak F., Ozaras R., Erdem L., Canbakan B., Mert A., Yurdakul I. Efficacy of pre-S-containing HBV vaccine combined with lamivudine in the treatment of chronic HBV infection. Dig. Dis. Sci. 2009, 54(9):2026.
69. Shi B., Ren G., Hu Y., Wang S., Zhang Z., Yuan Z. HBsAg inhibits IFN-α production in plasmacytoid dendritic cells through TNF-α and IL-10 induction in monocytes. PLoS One 2012, 7(9):e44900.
70. Shi H., Lu L., Zhang N.P., Zhang S.C., Shen X.Z. Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment. World J. Gastroenterol. 2012, 18(27):3617.
71. Stoop J.N., van der Molen R.G., Baan C.C., van der Laan L.J., Kuipers E.J., Kusters J.G., Janssen H.L. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005, 41(4):771.
72. Stoop J.N., Woltman A.M., Biesta P.J., Kusters J.G., Kuipers E.J., Janssen H.L., van der Molen R.G. Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. Hepatology 2007, 46(3):699.
73. Stross L., Günther J., Gasteiger G., Asen T., Graf S., Aichler M., Esposito I., Busch D.H., Knolle P., Sparwasser T., Protzer U. Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice. Hepatology 2012, 56(3):873.
74. Sun C., Fu B., Gao Y., Liao X., Sun R., Tian Z., Wei H. TGF-β1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence. PLoS Pathog. 2012, 8(3):e1002594.
75. Thermet A., Buronfosse T., Werle-Lapostolle B., Chevallier M., Pradat P., Trepo C., Zoulim F., Cova L. DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection. J. Gen. Virol. 2008, 89(Pt 5):1192.
76. Tjwa E.T., van Oord G.W., Hegmans J.P., Janssen H.L., Woltman A.M. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J. Hepatol. 2011, 54(2):209.
77. Tseng T.C., Liu C.J., Su T.H., Yang H.C., Wang C.C., Chen C.L., Kuo S.F., Liu C.H., Chen P.J., Chen D.S., Kao J.H. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation. J. Infect. Dis. 2012, 206(10):1521.
78. Tzeng H.T., Tsai H.F., Liao H.J., Lin Y.J., Chen L., Chen P.J., Hsu P.N. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. PLoS One 2012, 7(6):e39179.
79. van Zonneveld M., Zondervan P.E., Cakaloglu Y., Simon C., Akarca U.S., So T.M., Flink H.J., de Man R.A., Schalm S.W., Janssen H.L., HBV 99-01 Study Group Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int. 2006, 26(4):399.
80. Vassiliadis T., Tziomalos K., Patsiaoura K., Zagris T., Giouleme O., Soufleris K., Grammatikos N., Theodoropoulos K., Mpoumponaris A., Dona K., Zezos P., Nikolaidis N., Orfanou-Koumerkeridou E., Balaska A., Eugenidis N. Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. J. Gastroenterol. Hepatol. 2007, 22(10):1582.
81. Vincent I.E., Lucifora J., Durantel D., Hantz O., Chemin I., Zoulim F., Trepo C. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro. Antivir. Ther. 2009, 14(1):131.
82. Walsh R., Locarnini S. Hepatitis B precore protein: pathogenic potential and therapeutic promise. Yonsei Med. J. 2012, 53(5):875.
83. Wang S., Qiu L., Liu G., Li Y., Zhang X., Jin W., Gao G.F., Kong X., Meng S. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice. Vaccine 2011, 29(37):6342.
84. Woltman A.M., Op den Brouw M.L., Biesta P.J., Shi C.C., Janssen H.L. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS One 2011, 6(1):e15324.
85. Wooddell C.I., Rozema D.B., Hossbach M., John M., Hamilton H.L., Chu Q., Hegge J.O., Klein J.J., Wakefield D.H., Oropeza C.E., Deckert J., Roehl I., Jahn-Hofmann K., Hadwiger P., Vornlocher H.P., McLachlan A., Lewis D.L. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol. Ther. 2013, 21(5):973.
86. Wu J., Meng Z., Jiang M., et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009, 49(4):1132.
87. + T-cell response in patients with chronic hepatitis B. Eur. J. Immunol. 2012, 42(5):1180.
88. Xibing G., Xiaojuan Y., Juanhua W. PD-1 expression on CTL may be related to more severe liver damage in CHB patients with HBV genotype C than in those with genotype B infection. J. Viral Hepat. 2013, 20(4):e1.
89. Xiong S.Q., Lin B.L., Gao X., Tang H., Wu C.Y. IL-12 promotes HBV-specific central memory CD8+ T cell responses by PBMCs from chronic hepatitis B virus carriers. Int. Immunopharmacol. 2007, 7(5):578.
90. Yu Y., Wu H., Tang Z., Zang G. CTLA4 silencing with siRNA promotes deviation of Th1/Th2 in chronic hepatitis B patients. Cell. Mol. Immunol. 2009, 6(2):123.
91. Zhang Y.Y., Chen E.Q., Yang J., Duan Y.R., Tang H. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol. J. 2009, 6:63.
92. Zhang H.H., Mei M.H., Fei R., Liu F., Wang J.H., Liao W.J., Qin L.L., Wei L., Chen H.S. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses. J. Viral Hepat. 2010, 17(Suppl. 1):34.
93. Zheng P.Y., Zhang D.Y., Lu G.F., Yang P.C., Qi Y.M., Wang B.S. Effects of lamivudine on the function of dendritic cells derived from patients with chronic hepatitis B virus infection. World J. Gastroenterol. 2007, 13(34):4641.